FDA deems BI's AML drug volasertib 'breakthrough'
This article was originally published in Scrip
Executive Summary
Another oncology drug has won the US FDA's breakthrough therapy designation – this time Boehringer Ingelheim's volasertib, an inhibitor of polo-like kinase (Plk), which is under investigation to treat patients 65 years or older with previously untreated acute myeloid leukemia (AML) ineligible for intensive remission induction therapy.